Candida auris has emerged globally as a multidrug-resistant yeast that can spread via nosocomial 53
In less than a decade, C. auris has emerged in healthcare settings worldwide; this species is 72 capable of colonizing skin and causing outbreaks of invasive candidiasis. In contrast to other Candida 73 species, C. auris is unique in its ability to spread via nosocomial transmission and its high rates of drug 74 resistance. As part of the public health response, whole-genome sequencing has played a major role in 75 characterizing transmission dynamics and detecting new C. auris introductions. Through a global 76 collaboration, we assessed genome evolution of isolates of C. auris from 19 countries. Here, we 77 described estimated timing of the expansion of each C. auris clade and of fluconazole resistance, 78 characterized discrete phylogeographic population structure of each clade, and compared genome data to 79 sensitivity measurements to describe how antifungal resistance mechanisms vary across the population. 80
Introduction 84
In the last decade, Candida auris has emerged in healthcare settings as a multidrug-resistant 85 organism in over 30 countries worldwide (1). Primarily a skin colonizer, this pathogenic yeast can cause 86 bloodstream infections and other infections (2), is often resistant to multiple classes of antifungal drugs 87 (3, 4) , and can spread via nosocomial transmission causing outbreaks of invasive infections (5) (6) (7) (8) (9) (10) (11) (12) . 88
Initial studies suggested that C. auris emerged simultaneously and independently in four global 89 regions, as phylogenetic analyses revealed four major clades of C. auris wherein isolates clustered 90 geographically (13). These clades are referred to as the South Asian, East Asian, African, and South 91 American clades or clades I, II, III, and IV, respectively (14). The isolates from these clades are 92 genetically distinct, differing by tens to hundreds of thousands of single nucleotide polymorphisms 93 (SNPs), with nucleotide diversity nearly 17-fold higher between clades compared to within clades (14) . 94
All the clades, except Clade II, have been linked to outbreaks of invasive infections; uniquely, Clade II 95 appears to have a propensity for ear infections (15). The need for increased global efforts to understand 96 the population structure of C. auris was recently highlighted by the discovery of the first Iranian C. auris 97 case that yielded a single isolate representing a fifth major clade (16) . 98
Molecular epidemiologic investigations of C. auris outbreaks generally show clusters of highly 99 related isolates, supporting local and ongoing transmission (7, 17, 18) . The analysis of outbreaks and 100 individual cases has also revealed genetic complexity, with isolates from different clades detected in 101 6 different clades and opposing mating types overlap in time and space. This information could help 108 contextualize complex epidemiologic findings or transmission dynamics. 109
In addition to its transmissibility, C. auris is concerning because of its high rates of drug 110 resistance. Three major classes of antifungal drugs are currently approved for systemic use -azoles, 111 polyenes, and echinocandins. Most C. auris isolates are resistant to fluconazole (azole) (22). Elevated 112 minimal inhibitory concentrations (MICs) to amphotericin B (polyene) have been reported in several 113 studies and resistance to echinocandins is emerging in some countries (22) . Numerous mechanisms of 114 antifungal resistance have been described for C. auris. Echinocandin resistance has been linked to a 115 single mutation at S639P/F in FKS1, the gene that encodes the echinocandin target 1,3-beta-D-glucan 116 synthase (23). Most isolates display a mutation linked to fluconazole resistance in C. albicans; three 117 mutations, Y132F, K143R, and F126L, have been identified in ERG11, the gene that encodes the azole 118 target lanosterol 14-α-demethylase. These mutations have been shown to associate by clade where 119 Y132F and K143R are predominately found in Clades I and IV and F126L is exclusively in Clade III 120 (13, 24). Additionally, there have been suggestions that increased copy number of ERG11 may be a 121 mechanism for fluconazole resistance in C. auris (14) . 122
To better understand C. auris emergence and population structure, we engaged in a global 123 collaboration involving 19 countries to produce a large dataset of C. auris whole-genome sequences 124 from hundreds of cases and associated environmental samples from healthcare surfaces. Our goal was to 125 generate a comprehensive genomic description of a global C. auris population to provide a population 126 genetic framework for the molecular epidemiologic investigations. 127
In contrast to an initial report (13), we observed a weaker phylogeographic substructure as 140 isolates from countries of most global regions appeared interspersed in phylogenies, although there was 141 notable clustering by country within Clade IV ( Figure 1C) To better understand the emergence of this species, we next estimated the divergence times of 154 the four major clades. We utilized collection dates for clinical isolates and associated environmental 155 samples, such as swabs from healthcare facilities, which ranged from 2004 to 2018; most (98%) were 156 collected from 2012 to 2018 (Figure 2A) . By analyzing Clade III isolates from a single healthcare 157 facility in Kenya experiencing an outbreak of ongoing transmission (25), we confirmed that the 158 divergence level of these isolates are temporally corelated, supporting use of molecular clock analyses, 159 and calculated a mutation rate of 1.8695 e-5 substitutions per site per year (Supplementary Figure 1) . 160
This rate was used for a Bayesian approach for molecular dating of a phylogeny for all four clades. 161
Using a strict clock coalescent model, we estimated that the time to most recent common ancestor 162 (TMRCA) for each clade occurred within the last 339 years (Figure 2B corresponding to Clades I, II, III, and IV, and the tight clustering of isolates within each clade suggests 181 there is no recent admixture in any isolates ( Figure 3A) . To assess genetic diversity at the clade level, 182 we compared population genetic statistics, including nucleotide diversity (π), Tajima's D (TD), fixation 183 index (FST) and pairwise nucleotide diversity (DXY) (Figure 3B to E) . Overall, Clade I and III showed 184 the lowest genetic diversity (π = 1.51e-5 and π = 1.42e-5, respectively); Clade IV exhibited nearly three 185 times these levels (π = 4.23e-5) and Clade II presented the highest genetic diversity (π = 1.29e-4), nearly 186 nine times higher than Clades I and III (Figure 3B) . Clade II was also the only clade that exhibited 187 positive TD (td = 1.153; Figure 3B population divergence between C. auris clades. Even between these clades with substantial interspecific 201 divergence, we detected large genomic tracts that exhibit either high or low DXY values. For DXY, we 202 observed that all chromosomes exhibited a bimodal distribution of regions of both high and low levels of 203 DXY; scaffolds 8 and 10, which correspond to chromosomes 1 and 3, respectively (14), show only low 204 DXY values (Figure 3E; Supplementary Figure 2 ). DXY is expected to be elevated in regions of limited 205 gene flow, which could have arisen in C. auris due to chromosomal rearrangements between the clades 206 (26, 27), whereas DXY is unchanged or decreased in regions under recurrent background selection or 207 selective sweeps. 208
We observed a single C. auris mating type in each clade. Isolates in Clades I and IV had MTLa 209 and those in Clades II and III had MTLα (Supplementary Figure 4) ; this confirms prior findings from a 210 smaller data set (14) in this larger global survey. Countries with multiple clades (i.e., Canada, Kenya, 211 and United States) had isolates of opposite mating types; however, there is no evidence of hybridization 212 between clades within these countries or even between isolates of opposite mating types that were 213 observed contemporaneously in a single healthcare facility in Kenya based on the PCA analysis. 214
Together, these findings suggest that the C. auris clades have been genetically isolated and that variation 215 across the genome was likely impacted by karyotype variation that prevented equal chromosome 216 mixing. 217
218
Antifungal drug resistance and mechanisms of resistance 219
To examine resistance levels, we performed antifungal susceptibility testing (AFST) to 220 fluconazole, amphotericin B, and micafungin -drugs representing each of the major classes. Of the 294 221 isolates tested, 80% were resistant to fluconazole, 23% to amphotericin B, and 7% to micafungin (Table  222 1, Figure 4 ). Clade II had the greatest percentage (86%) of susceptible isolates, including only one 223 isolate resistant to fluconazole, and Clade I had the greatest percentage of resistant isolates to 224 fluconazole (97%) and amphotericin B (54%). Additionally, Clade I had the highest rates of multidrug-225 resistance (two antifungal classes; 49%) and was the only clade to have extensive drug-resistance (3%) 226 to all three major classes of antifungals, including isolates from two geographic regions (United Arab 227
Emirates and Kenya) that cluster together (Table 1; Figure 4 ). Amphotericin B resistance only appeared 228 in Clades I and IV, and was dispersed across the phylogeny in Clade I and detected in a Clade IV cluster 229 of isolates from Colombia. Clade IV also had the highest percentage (9%) resistant to micafungin, all 230 isolates from Venezuela. Micafungin resistance appeared sporadically in the phylogenies of Clades I and 231
III. 232
We next determined the genotype of specific drug mutations in the ERG11 gene that have been 233 associated with azole resistance (Y132F, K143R and F126L). The most widespread mutation was 234 Y132F spanning 11 countries in 53% of isolates from Clade I and 40% of isolates from Clade IV 235 (Figure 4) . ERG11 K143R was predominately found in a subclade within Clade I (43%) and one isolate 236 from Clade IV. F126L was found only in Clade III, in nearly all isolates (96%) (Figure 4) ; all isolates 237 with F126L also carried the adjacent mutation V125A. Nearly all of the isolates with these changes in 238 ERG11 were resistant to fluconazole; 99% of the isolates with Y132F or K143R and 100% of the 239 isolates with F126L/V125A appeared resistant to fluconazole (MIC ≥32 µg/mL). We also identified 240 polymorphisms in S639 in the hotspot1 of the FKS1 gene in 90% of the isolates with decreased 241 susceptibility to micafungin. The most frequent mutation was S639P in 13 isolates from Clade IV (11 242 resistant to micafungin), and S639F and S639Y were found in micafungin-resistant isolates from Clade I 243 and III (Figure 4) . 244
Analysis of the distribution of ERG11 copy number variation (CNV) revealed that of 304 245 isolates, 18 (6%) had either two or three copies. Of those 18 isolates, all were resistant to fluconazole 246 and 17 (94%) were from Clade III (Supplementary Figure 5) . Isolates within Clade III with 2 and 3 247 copies of ERG11 had significantly higher MICs (P ≤ 0.05; Mann-Whitney test) to fluconazole than 248 isolates with one copy (Supplementary Figure 5) . Along with CNVs in ERG11, we found a total of six 249 long regions (>40 kb) that showed increased copy number. Unlike CNVs in ERG11, these CNVs 250 appeared in single isolates even in highly clonal clusters, with two isolates in each of Clades I, II, and IV 251 Figure 6) . While genes in these regions (between 23 and 125 genes in each region) 252 have no direct relation with antifungal resistance, they might play a role in microevolution and C. auris 253 adaptation to host stress. This includes genes associated with response to oxidative stress (AOX2, 254 HSP12), iron assimilation (FET33, FTR1, CHA1, FLC1), cell wall and membrane integrity (MNN2, 255 ERG5, ERG24), a transcription factor (ZCF16) and oligopeptide transporters associated with metabolic 256 and morphologic adaptation and adherence ( Supplementary Table 2 ). These data provide insight into 257 the underlying molecular mechanisms of antifungal resistance and suggest that CNV could be a 258 mechanism of strain variation in C. auris. Further exploration and monitoring of these traits are crucial 259 to improve our understanding of C. auris diversity and control the expanding outbreak. 260 261 Discussion 262
In this study, we used whole-genome sequencing to describe a global collection of C. auris 263 isolates collected from patients and healthcare facilities between 2004 and 2018. We found that the four 264 predominant clades are genetically distinct with strong geographic substructure in Clade IV. Using 265 collection dates to estimate a molecular clock, we dated the origins of the four clades and confirmed the 266 recent emergence of C. auris. Furthermore, we characterized mutations associated with antifungal 267 resistance by clade, which varied between clades and country of isolation. While the clades appear 268 largely clonal in species phylogenies and represent a single mating type, we found that they have distinct 269 evolutionary histories and genome-wide patterns of variation. We provided a browsable version for C. 270 auris genomic epidemiology through Microreact (28) to explore phylogeny, geographic distribution, 271 timeline and drug resistance mutations (https://microreact.org/project/wfwXVjf9G). 272
In contrast to previous reports, we observed more phylogeographic mixing for C. auris (13). 273
While we found that isolates from additional global regions can be clearly assigned to one of the four 274 previously reported clades, we observed that three countries -Canada, Kenya, and United States -had 275 isolates corresponding to multiple C. auris clades (Figure 1B) . Additionally, isolates from multiple 276 clades have been previously reported in Germany (19) and the United Kingdom (20). As travel has been 277 previously shown to play a major role in the spread of C. auris (21), global travel of persons with prior 278 healthcare exposures to C. auris has likely contributed to the observed phylogeographic mixing. Our 279 analysis of the likely geographic origin of infections observed in new geographic regions is limited by 280 incomplete travel history for most patients in this study set. We noted that the strongest geographic 281 substructure was observed in Clade IV for isolates from Colombia, Panama and Venezuela, with 282 additional distinct clades of isolates from Israel and United States (Figure 1C) . This finding further 283 supports evidence of rapid localized transmission in some of these countries (18, 21). 284
These results have confirmed prior findings from the analysis of a smaller data set where isolates 285
in Clades I and IV had MTLa and those in Clades II and III had MTLα (14). Although mating between 286 C. auris clades has not been reported, it is concerning that the majority of countries reporting multiple C. highlighted by the detection of regions with very low FST values, which suggest recent divergence or 296 genetic exchange between these clades. Given that these regions were short and spread across the 297 genome, we hypothesized that they are a result of incomplete lineage sorting rather than recent 298 introgression events. We also observed variation in the average divergence between clades (DXY) along 299 each chromosome. This may be due to genome rearrangements between the clades, whereby genomic rearrangements, which prevents recombination and supports high rates of genetic differentiation. 302
Variation in chromosome number and size as measured by electrophoretic karyotyping as well as 303 deletions, inversions and translocations detected by comparing genome assemblies of different C. auris 304 clade isolates have been described in C. auris (14, 26, 27) . 305
This global survey has provided a wider perspective of the mechanisms and the frequency of 306 mutations associated with resistance to antifungal drugs. The presence of both resistant and susceptible 307 isolates in the same populations along with the presence of genetically related isolates with different 308 alleles of resistance genes indicate that the resistance in C. auris is not intrinsic and has been recently 309 acquired. The most common mutation associated with azole resistance in Clades I and IV was ERG11 310 Y132F; however, both clades also included genetically related isolates with ERG11 K143R. In contrast, 311 all fluconazole resistant isolates in Clade III carried ERG11 F126L substitution. In addition to mutations 312 in genes associated with drug resistance, we found that increase in copy number of ERG11 is 313 predominantly observed in Clade III again suggesting clade specific variation in mechanisms of azole 314 resistance. All but three isolates with micafungin resistance had FKS1 S639Y/P/F mutations. Taken Conversely, three other clades had low genetic diversity and negative TD consistent with the rapid 328 emergence. Notably, the oldest C. auris isolate was collected from a patient in South Korea in 1996 (2) 329 and no other strains were identified by searching the historic Candida culture collections. The absence 330 of C. auris in culture collections prior to 1996 and a rapid emergence after 2012 suggest that this 331 organism only recently emerged as a human pathogen and likely occupied a different ecological niche. 332
Other notable fungal outbreaks also have been estimated to be of recent origin. For example, the 333 BdGPL lineage of the amphibian pathogen Batrachochytrium dendrobatidis was estimated to have 334 arisen only ~100 years ago (29). While our reported mutation rate of 1.8695 e-5 substitutions per site is 335 consistent with that (5.7 e-5 ; R 2 = 0.37) reported in a previous study (17), the mutation rate over longer 336 time spans than we sampled is likely slower. We used collection dates spanning from 2004 to 2018 to 337 inform our estimate, and rates of molecular evolution measured over short time-scales tend to be 338 overestimated, as some sites will be removed over time by natural selection (30). Therefore, the rate is 339 more similar to a spontaneous mutation rather than an evolutionary substitution rate. If our mutation rate 340 is substantially overestimated, the exact times of C. auris emergence and clade divergence would be 341 older than we have estimated. We also acknowledge that utilizing only currently known isolates, which 342 are highly similar within clades, provides a limited sampling of a larger source population, which may 343 be also be undergoing sexual recombination. The identification and characterization of a wider 344 population sample of C. auris will provide a higher resolution view of the nodes separating these major 345 clades. However, as there is only speculation to date about potential associations or locations of such a 346 source population, we suggest that the dates reported be used as a rough estimate that will need further 347 evaluation when sources of additional diversity are identified. brought C. auris into contact with humans (35). Although the emergence of C. auris may be due to 362 multiple factors, the coincidence between the introduction of azoles and C. auris emergence is intriguing 363 and requires further investigation. Understanding processes that led to the emergence of C. auris in 364 humans is important to prevent emergence of other drug resistant fungi and pathogens. 365
Although a recent study reported an isolate from a fifth clade isolated from a patient in Iran (16), 366 all isolates in our collection were assigned to the previously described Clades I, II, III, and IV. This is 367 noteworthy because isolates from neighboring Pakistan, Saudi Arabia, and United Arab Emirates were 368 represented in the analysis. Indeed, this highlights the unique nature of the divergent Iranian C. auris 369 case and advocates for increasing diagnostic capacity worldwide and continued phylogenetic studies to 370 understand C. auris diversity. 371 While we have included a set of diverse isolates, they likely differ from a random sample of the 372 C. auris population. The isolates were obtained by conventional sampling, and, therefore, our findings 373 do not represent country-specific characteristics of C. auris molecular epidemiology. Wider sampling 374 may also change the population structure and antifungal susceptibility profiles. Notably, at the time of 375 this analysis, Clade V had not yet been discovered, highlighting the importance of further sampling and 376 genomic characterization. Finally, since the environmental reservoir of C. auris remains unknown, our 377 analysis is based solely on the analysis of clinical isolates; higher genetic diversity, deeper divergence 378 times and different population structure is likely to occur in the natural populations of this fungus. 379
In conclusion, we have provided a comprehensive genomic description of a global C. auris 380 survey representing 19 countries on six continents. Given that C. auris is a transmissible multidrug-381 resistant organism causing outbreaks of invasive infections in healthcare studies, an understanding of 382 how C. auris is spreading, evolving, and acquiring resistance to antifungal drugs is essential for robust 383 public health responses. Continued efforts to characterize the C. auris population, additional 384 mechanisms of antifungal resistance, and environments conducive for mating between clades is critical. 385 386 Methods 387
Sample collection 388
We performed genomic analyses on sequences from 304 C. auris isolates. This collection 389 included C. auris from 19 countries on six continents and were sampled from both C. auris cases and 390 environmental surfaces from healthcare facilities where ongoing transmission was occurring 391
( Supplementary Table 1 ). Samples from C. auris cases were derived from a variety of specimen source 392 sites including sterile sites, such as blood, and non-invasive sites, such as respiratory tract or urine. All 393 samples were a result of convenience sampling. For four countries (Colombia, Kenya, United States, and 394 Venezuela) where more than 50 samples were available, 50 representative samples were selected by 395 proportional random sampling: samples from each country were stratified by city, and then a subset was 396 randomly selected proportionally from each strata. 397 398
Sample preparation and whole-genome sequencing (WGS) 399
The sample collection comprised both publicly available sequences generated from previous 400 studies and newly sequenced isolates ( Supplementary Table 1 
Variant identification 412
We used FastQC v0.11.5 and PRINSEQ v0.20.3 (36) to assess read quality and perform filtering 413 for low quality sequences using "-trim_left 15 -trim_qual_left 20 -trim_qual_right 20 -min_len 100 -414 min_qual_mean 25 -derep 14". Paired-end reads were aligned to the C. auris assembly strain B8441 415 (GenBank accession PEKT00000000.2; (14)) using BWA mem v0.7.12 (37) . Variants were then 416 identified using GATK v3.7 (38) using the haploid mode and GATK tools RealignerTargetCreator, 19 "QD < 2.0 || FS > 60.0 || MQ < 40.0". Genotypes were filtered if the minimum genotype quality < 50, 420 percent alternate allele < 0.8, or depth < 10 (https://github.com/broadinstitute/broad-421 fungalgroup/blob/master/scripts/SNPs/filterGatkGenotypes.py). Genomic variants were annotated and 422 the functional effect was predicted using SnpEff v4.3T (39). The annotated VCF file was used to 423 determine the genotype of known mutation sites in ERG11 and FKS1. To determine the mating type 424 locus (MTLa and MTLα) in each isolate, the average read depth at the locus was computed from the 425 aligned bam file and normalized by the total coverage depth. 426 427
Phylogenetic and phylodynamic analysis 428
For phylogenetic analysis, sites with an unambiguous SNP in at least 10% of the isolates (n = 429 222,619) were concatenated. Maximum likelihood phylogenies were constructed using RAxML v8.2.4 430 (40) using the GTRCAT nucleotide substitution model and bootstrap analysis based on 1,000 replicates. 431
Phylogenetic analysis was also performed for each clade using subsets of the entire VCF and visualized 432 using iTOL (41). 433
For phylodynamic analysis, we assessed for a temporal signal using a set of isolates from Kenya 434 Clade III using TempEst v1.5.3 (42) to quantify and to estimate an initial mutation rate from the R-435 squared value. Bayesian phylogenies were generated using BEAST v1.8.4 (43) under strict molecular 436 clock (both lognormal and exponential priors). In addition, we applied both Bayesian Skyline coalescent 437 and Coalescent Exponential, and a GTR nucleotide substitution model. We obtained similar results 438 using the molecular rate estimated for a C. auris outbreak un United Kingdom (17). Specimen collection 439 dates (month and year) were used as sampling dates; the month of June (year midpoint) was assigned for 440 samples where month was unknown. Bayesian Markov chain Monte Carlo (MCMC) analyses were run 441 for 20 million steps using an unweighted pair-group method with arithmetic mean (UPGMA) tree as a 442 starting tree and MCMC convergence was explored using Tracer v.1.7.1 (44). We generated a maximum 443 clade credibility tree with TreeAnnotator v1.8.4 after discarding 47% as burn-in, and we visualized 444 Oakwood Village, OH, USA) were used for fluconazole and the echinocandin micafungin. Interpretive 459 breakpoints for C. auris were defined based on a combination of those breakpoints which have been 460 established for other closely related Candida species, epidemiologic cutoff values, and the biphasic 461 distribution of minimum inhibitory concentrations (MICs) between the isolates with and without known 462 mutations for antifungal resistance. Resistance to fluconazole was set at ≥32 µg/mL and at ≥4 µg/mL for 463 micafungin. Amphotericin B was assessed by Etests (BioMerieux), and resistance was set at ≥2 µg/mL. 464
For isolates not tested at the CDC, similar methods were employed and described previously (17, 19, 465 48). As there are no currently approved breakpoints for C. auris, for this manuscript breakpoints were 466 set at ≥32 µg/mL for fluconazole, >1 µg/mL for amphotericin B, and ≥4 for micafungin. These MIC 467 values were based on a combination of the wild type distribution (those isolates with no mutations) and 468 PK/PD analysis in a mouse model of infection (49 
